title: Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.
authors.forename: Beata
authors.initials: B
authors.lastname: Holkova
authors.forename: Steven
authors.initials: S
authors.lastname: Grant
mesh_terms: D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005419:Flavonoids / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D016328:NF-kappa B / Q000378:metabolism; D010880:Piperidines / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use
chemical_list: D001897:Boronic Acids; D004791:Enzyme Inhibitors; D005419:Flavonoids; D016328:NF-kappa B; D010880:Piperidines; D061988:Proteasome Inhibitors; D011719:Pyrazines; C077990:alvocidib; D000069286:Bortezomib; D018844:Cyclin-Dependent Kinases; D046988:Proteasome Endopeptidase Complex